Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 28, 2017

Biohaven concludes enrolment in BHV3000-302 trial for migraines

Biohaven Pharmaceutical has concluded patient enrolment in the second Phase III clinical trial (Study BHV3000-302) of its drug candidate rimegepant for the acute treatment of migraines.

Biohaven Pharmaceutical has concluded patient enrolment in the second Phase III clinical trial (Study BHV3000-302) of its drug candidate rimegepant for the acute treatment of migraines.

Rimegepant is an oral, second-generation antagonist of calcitonin gene-related peptide (CGRP) receptor.

The double-blind, placebo-controlled Phase III trial is designed to evaluate the safety and efficacy of 75mg rimegepant.

Study BHV3000-302 is set to measure the co-primary endpoints of freedom from pain and patient’s most bothersome symptom such as nausea, photophobia or phonophobia at two hours after dosing.

Biohaven Pharmaceutical CEO VladCoric said: “Completion of enrolment in this second migraine trial in only about four months underscores both the priority of the CGRP programme within Biohaven and the very high unmet need for innovative therapies to better treat migraine attacks.

“Completion of enrolment in this second migraine trial in only about four months underscores both the priority of the CGRP programme.”

“Rimegepant was designed to be highly potent at the CGRP receptor and administered orally to allow convenient dosing by migraine sufferers when and where a migraine attack hits.”

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Earlier this month, the firm announced the completion of patient recruitment in another Phase III trial, Study BHV3000-301, of rimegepant for the acute treatment of a migraine.

With a total of about 3,000 subjects, both the trials are scheduled to report top-line data in the first quarter of next year.

The findings from this Phase III migraine programme are expected to support the efficacy of the investigational agent as required for registration by the US Food and Drug Administration (FDA).

The firm has also recently obtained agreement from the FDA on the initial paediatric study plan (iPSP) for orally dosed rimegepant.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU